pioneering next generation approaches to cure neurological conditions.
RECENT NEWS
Kenai Therapeutics Appoints Blake Arnold, CFA, as Chief Business Officer
Kenai Therapeutics, a clinical-stage biotechnology company pioneering next generation approaches to cure neurological conditions, today announced the appointment of Blake Arnold, CFA, as Chief Business Officer. In this role, Mr. Arnold will lead Kenai’s business development, financing, strategic partnerships and corporate development initiatives to support the company’s clinical and pipeline growth.
meet kenai therapeutics
We are a clinical-stage biotechnology company advancing off-the-shelf dopamine neuron replacement cell therapies and gene-modified medicines for the treatment of neurological conditions. Our aim is to deliver disease-modifying and potentially curative treatments that go beyond symptom management to reverse the impact of neurodegeneration – with the goal of restoring quality of life.